- Home
- LWLG vs KALV Comparison
LWLG vs KALV Comparison
Compare LWLG & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWLG
- KALV
- Stock Information
- Founded
- LWLG 1991
- KALV N/A
- Country
- LWLG United States
- KALV United States
- Employees
- LWLG N/A
- KALV N/A
- Industry
- LWLG Containers/Packaging
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- LWLG Industrials
- KALV Health Care
- Exchange
- LWLG Nasdaq
- KALV Nasdaq
- Market Cap
- LWLG 549.2M
- KALV 551.2M
- IPO Year
- LWLG N/A
- KALV N/A
- Fundamental
- Price
- LWLG $4.38
- KALV $14.11
- Analyst Decision
- LWLG
- KALV Strong Buy
- Analyst Count
- LWLG 0
- KALV 8
- Target Price
- LWLG N/A
- KALV $26.43
- AVG Volume (30 Days)
- LWLG 1.4M
- KALV 1.3M
- Earning Date
- LWLG 11-14-2025
- KALV 11-10-2025
- Dividend Yield
- LWLG N/A
- KALV N/A
- EPS Growth
- LWLG N/A
- KALV N/A
- EPS
- LWLG N/A
- KALV N/A
- Revenue
- LWLG $100,605.00
- KALV $1,426,000.00
- Revenue This Year
- LWLG N/A
- KALV N/A
- Revenue Next Year
- LWLG N/A
- KALV $234.65
- P/E Ratio
- LWLG N/A
- KALV N/A
- Revenue Growth
- LWLG N/A
- KALV N/A
- 52 Week Low
- LWLG $0.79
- KALV $7.30
- 52 Week High
- LWLG $6.26
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- LWLG 44.72
- KALV 64.03
- Support Level
- LWLG $3.90
- KALV $12.82
- Resistance Level
- LWLG $4.62
- KALV $13.75
- Average True Range (ATR)
- LWLG 0.51
- KALV 0.93
- MACD
- LWLG -0.10
- KALV 0.14
- Stochastic Oscillator
- LWLG 22.12
- KALV 81.91
About LWLG Lightwave Logic Inc.
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.